Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

6.949 +0.159 (+2.34%)
Streaming Delayed Price Updated: 9:48 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action
Via Investor Brand Network
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
MarketBeat Week in Review – 12/18 - 12/22
The torrid stock market rally cooled down a little bit heading into the extended holiday weekend; we wish you a Happy Holiday season with friends and family 
Via MarketBeat
Topics Economy
Exposures Interest Rates
C4 Therapeutics blasts off: what's next?
As the market soars to new heights, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to explode higher in price and volume. 
Via MarketBeat
Topics ETFs
C4 Therapeutics Inc. (NASDAQ: CCCC) Near Top of Volume Charts in Friday Trading
Via Investor Brand Network
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Thursday Morning’s Most Active Stocks
Via Investor Brand Network
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
Initial Focus on One Oncology Target, Exclusive to Collaboration; Merck has Option for Three Additional Targets 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the Board of Directors 
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Chief Financial Officer Succession
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
From C4 Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.